[Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer].
OBJECTIVE
To evaluate the efficacy and adverse effects of irinotecan combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).


METHODS
Fifteen patients (10 males and 5 females) aged from 32 to 58 years (median age of 47 years) with KPS>70 and the diagnosis of advanced NSCLC by pathology or cytology were treated with cisplatin 80 mg/m(2) plus irinotecan 60 mg/m(2) by intravenous infusion on 1, 8, 15 days, and the treatment was repeated every 4 weeks. After treatment for at least 2 cycles, the therapeutic effects and adverse drug reactions were evaluated.


RESULTS
Of all the cases, PR was achieved in 4 (26.7%), SD in 9 (60%), and PD in 2 (13.3%), with an overall response rate of 26.7%. The median survival time was 11 months and 1-year survival rate was 46.7% (7/15). The main toxicities were delayed diarrhea and granulocytopenia.


CONCLUSIONS
Irinotecan plus cisplatin is an effective and tolerable treatment for advanced NSCLC with low incidence of adverse effects.
Han
Na
N
Department of Oncology, Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China. hannana2005@yahoo.cn
Liu
Zong-wen
ZW
Wang
Jian
J
Zhang
Zhong-mian
ZM
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin